Credit: Reuters/Phil Noble
A sign is seen at an AstraZeneca site in Macclesfield, central England May 19, 2014.
Britain's second biggest drugmaker - subject of a takeover bid by Pfizer that failed last month - said on Thursday it would pay UK-based Synairgen a $7.25 million upfront fee and potential development, regulatory and commercial milestones of up to $225 million for rights to SNG001.
(Reporting by Ben Hirschler, Editing by Paul Sandle)
